Cargando…
Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?
BACKGROUND: Sarcopenia has emerged as an important parameter to predict outcomes and treatment toxicity. However, limited data are available to assess sarcopenia prevalence in metastatic breast cancer and to evaluate its management. METHODS: The SCAN study was a cross-sectional multicenter French st...
Autores principales: | Deluche, Elise, Lachatre, Denis, Di Palma, Mario, Simon, Hélène, Tissot, Valentin, Vansteene, Damien, Meingan, Philippe, Mohebi, Alexis, Lenczner, Grégory, Pigneur, Francois, Goldwasser, Francois, Raynard, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693346/ https://www.ncbi.nlm.nih.gov/pubmed/34923226 http://dx.doi.org/10.1016/j.breast.2021.12.014 |
Ejemplares similares
-
The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study)
por: Raynard, Bruno, et al.
Publicado: (2021) -
Psoas muscle index is not representative of skeletal muscle index for evaluating cancer sarcopenia
por: Pigneur, Frédéric, et al.
Publicado: (2023) -
Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012) -
Can the Six-Minute Walk Test Be Used to Individualize Physical Activity Intensity in Patients with Breast Cancer?
por: Tubiana-Mathieu, Nicole, et al.
Publicado: (2021) -
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
por: Cabel, Luc, et al.
Publicado: (2021)